BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 37171742)

  • 1. JAK Inhibition in Aicardi-Goutières Syndrome: a Monocentric Multidisciplinary Real-World Approach Study.
    Frémond ML; Hully M; Fournier B; Barrois R; Lévy R; Aubart M; Castelle M; Chabalier D; Gins C; Sarda E; Al Adba B; Couderc S; D' Almeida C; Berat CM; Durrleman C; Espil C; Lambert L; Méni C; Périvier M; Pillet P; Polivka L; Schiff M; Todosi C; Uettwiller F; Lepelley A; Rice GI; Seabra L; Sanquer S; Hulin A; Pressiat C; Goldwirt L; Bondet V; Duffy D; Moshous D; Bader-Meunier B; Bodemer C; Robin-Renaldo F; Boddaert N; Blanche S; Desguerre I; Crow YJ; Neven B
    J Clin Immunol; 2023 Aug; 43(6):1436-1447. PubMed ID: 37171742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutations in RNU7-1 Weaken Secondary RNA Structure, Induce MCP-1 and CXCL10 in CSF, and Result in Aicardi-Goutières Syndrome with Severe End-Organ Involvement.
    Naesens L; Nemegeer J; Roelens F; Vallaeys L; Meuwissen M; Janssens K; Verloo P; Ogunjimi B; Hemelsoet D; ; Hoste L; Roels L; De Bruyne M; De Baere E; Van Dorpe J; Dendooven A; Sieben A; Rice GI; Kerre T; Beyaert R; Uggenti C; Crow YJ; Tavernier SJ; Maelfait J; Haerynck F
    J Clin Immunol; 2022 Jul; 42(5):962-974. PubMed ID: 35320431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aicardi-Goutieres syndrome, a rare neurological disease in children: a new autoimmune disorder?
    Fazzi E; Cattalini M; Orcesi S; Tincani A; Andreoli L; Balottin U; De Simone M; Fredi M; Facchetti F; Galli J; Giliani S; Izzotti A; Meini A; Olivieri I; Plebani A
    Autoimmun Rev; 2013 Feb; 12(4):506-9. PubMed ID: 22940555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aicardi-Goutières syndrome: A monogenic type I interferonopathy.
    Liu A; Ying S
    Scand J Immunol; 2023 Oct; 98(4):e13314. PubMed ID: 37515439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neonatal detection of Aicardi Goutières Syndrome by increased C26:0 lysophosphatidylcholine and interferon signature on newborn screening blood spots.
    Armangue T; Orsini JJ; Takanohashi A; Gavazzi F; Conant A; Ulrick N; Morrissey MA; Nahhas N; Helman G; Gordish-Dressman H; Orcesi S; Tonduti D; Stutterd C; van Haren K; Toro C; Iglesias AD; van der Knaap MS; Goldbach Mansky R; Moser AB; Jones RO; Vanderver A
    Mol Genet Metab; 2017 Nov; 122(3):134-139. PubMed ID: 28739201
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interstitial Lung Disease and Psoriasis in a Child With Aicardi-Goutières Syndrome.
    Zheng S; Lee PY; Wang J; Wang S; Huang Q; Huang Y; Liu Y; Zhou Q; Li T
    Front Immunol; 2020; 11():985. PubMed ID: 32508843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bilateral striatal necrosis in two subjects with Aicardi-Goutières syndrome due to mutations in ADAR1 (AGS6).
    La Piana R; Uggetti C; Olivieri I; Tonduti D; Balottin U; Fazzi E; Orcesi S
    Am J Med Genet A; 2014 Mar; 164A(3):815-9. PubMed ID: 24376015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sine causa tetraparesis: A pilot study on its possible relationship with interferon signature analysis and Aicardi Goutières syndrome related genes analysis.
    Galli J; Gavazzi F; De Simone M; Giliani S; Garau J; Valente M; Vairo D; Cattalini M; Mortilla M; Andreoli L; Badolato R; Bianchi M; Carabellese N; Cereda C; Ferraro R; Facchetti F; Fredi M; Gualdi G; Lorenzi L; Meini A; Orcesi S; Tincani A; Zanola A; Rice G; Fazzi E;
    Medicine (Baltimore); 2018 Dec; 97(52):e13893. PubMed ID: 30593198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical spectrum and currently available treatment of type I interferonopathy Aicardi-Goutières syndrome.
    Dell'Isola GB; Dini G; Culpepper KL; Portwood KE; Ferrara P; Di Cara G; Verrotti A; Lodolo M
    World J Pediatr; 2023 Jul; 19(7):635-643. PubMed ID: 36650407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Astrocytes, an active player in Aicardi-Goutières syndrome.
    Sase S; Takanohashi A; Vanderver A; Almad A
    Brain Pathol; 2018 May; 28(3):399-407. PubMed ID: 29740948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapies in Aicardi-Goutières syndrome.
    Crow YJ; Vanderver A; Orcesi S; Kuijpers TW; Rice GI
    Clin Exp Immunol; 2014 Jan; 175(1):1-8. PubMed ID: 23607857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cerebrospinal fluid neopterin as a biomarker of treatment response to Janus kinase inhibition in Aicardi-Goutières syndrome.
    Han VX; Mohammad SS; Jones HF; Bandodkar S; Crow YJ; Dale RC;
    Dev Med Child Neurol; 2022 Feb; 64(2):266-271. PubMed ID: 34415581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inflammatory myopathy in a patient with Aicardi-Goutières syndrome.
    Tumienė B; Voisin N; Preikšaitienė E; Petroška D; Grikinienė J; Samaitienė R; Utkus A; Reymond A; Kučinskas V
    Eur J Med Genet; 2017 Mar; 60(3):154-158. PubMed ID: 28089741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Child Neurology: Aicardi-Goutières Syndrome Presenting as Recurrent Ischemic Stroke.
    Kuang SY; Li Y; Yang SL; Han X
    Neurology; 2022 Aug; 99(9):393-398. PubMed ID: 35803721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuropathologic Impacts of JAK Inhibitor Treatment in Aicardi-Goutières Syndrome.
    Jafarpour S; Suddock J; Hawes D; Santoro JD
    J Clin Immunol; 2024 Feb; 44(3):68. PubMed ID: 38381212
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Developmental Outcomes of Aicardi Goutières Syndrome.
    Adang L; Gavazzi F; De Simone M; Fazzi E; Galli J; Koh J; Kramer-Golinkoff J; De Giorgis V; Orcesi S; Peer K; Ulrick N; Woidill S; Shults J; Vanderver A
    J Child Neurol; 2020 Jan; 35(1):7-16. PubMed ID: 31559893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploring Autoimmunity in a Cohort of Children with Genetically Confirmed Aicardi-Goutières Syndrome.
    Cattalini M; Galli J; Andreoli L; Olivieri I; Ariaudo G; Fredi M; ; Orcesi S; Tincani A; Fazzi E
    J Clin Immunol; 2016 Oct; 36(7):693-9. PubMed ID: 27539236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dysregulation of the immune system in Aicardi-Goutières syndrome: another example in a TREX1-mutated patient.
    Olivieri I; Cattalini M; Tonduti D; La Piana R; Uggetti C; Galli J; Meini A; Tincani A; Moratto D; Fazzi E; Balottin U; Orcesi S
    Lupus; 2013 Sep; 22(10):1064-9. PubMed ID: 23918923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Variable clinical phenotype in two siblings with Aicardi-Goutières syndrome type 6 and a novel mutation in the ADAR gene.
    Schmelzer L; Smitka M; Wolf C; Lucas N; Tüngler V; Hahn G; Tzschach A; Di Donato N; Lee-Kirsch MA; von der Hagen M
    Eur J Paediatr Neurol; 2018 Jan; 22(1):186-189. PubMed ID: 29221912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Late-Onset Aicardi-Goutières Syndrome: A Characterization of Presenting Clinical Features.
    Piccoli C; Bronner N; Gavazzi F; Dubbs H; De Simone M; De Giorgis V; Orcesi S; Fazzi E; Galli J; Masnada S; Tonduti D; Varesio C; Vanderver A; Vossough A; Adang L
    Pediatr Neurol; 2021 Feb; 115():1-6. PubMed ID: 33307271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.